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Private Payer PerspectiveOur letter refers to the following publication: Wielage RC, Bansal
M, Andrews JS, et al. The cost-effectiveness of duloxetine in
chronic low back pain: a US private payer perspective. Value
Health 2013;16:334–44 [1]. We would like to draw attention to
several data inaccuracies in the mentioned article:1. The pain level of patients in the different publications is not
mentioned. We know from clinical trial experience with
tapentadol that patients had moderate to severe pain (most
even severe pain). Pain level of patients in studies with
duloxetine, naproxen, and celecoxib might have been lower;
at least we would extrapolate this from the dosages used. On
the basis of this, we doubt whether the study populations are
comparable and the comparators are appropriate. The patient
who uses naproxen (or even cox-II) is not similar to someone
who uses strong opioids.2. The dosage that is used for the calculation of daily costs of
tapentadol (Table 1 at http://dx.doi.org/10.1016/j.jval.2012.12.
006) with up to 600 mg is not within the label (according to the
SmPC, the highest dosage recommended is 500 mg/day) of the
extended release formulation recommended for the treatment
of chronic pain. The average dosages in clinical trials amount
to around 300 mg, with those from market data even lower
around 200 mg/day. The very high dosage used in the Wielage
et al. article leads to the high daily costs for tapentadol,
resulting in an unfavorable result for tapentadol in the
cost-effectiveness plane.3. The dosing for oxycodone extended release is not comparable
to the dosing for tapentadol. Comparing the World Health
Organization daily deﬁned dose, which is 400 mg for tapenta-
dol and 75 mg for oxycodone, this would be a factor of 5.3
(which is also reﬂected in the clinical trials in which oxyco-
done was used as active comparator [2]). The very low dosage
used for oxycodone (10–30 mg) would be suitable for patients
with mild to moderate pain, whereas the dosage of 600 mg for
tapentadol is even beyond the one covered by the labeled
indication and used in severe chronic pain and therefore
these are not comparable.4. Table 1 at http://dx.doi.org/10.1016/j.jval.2012.12.006: PPI (Pro
ton Pump Inhibitor) use for all opioids is high, 21%. It is not
clear why is this higher than for nonsteroidal anti-in-
ﬂammatory drugs, and the source of these data is not given.
Because the main adverse events for opioids are nausea,
vomiting, and constipation (which cannot be treated withial support: The authors have no other ﬁnancial relaPPIs), we do not see a causal relationship between opioid
treatment and the use of PPIs at all.5. Table 1 at http://dx.doi.org/10.1016/j.jval.2012.12.006: How are
“discontinuation drug costs” deﬁned? Why are they so high for
tapentadol than for other therapies? In clinical trials, the percen
tage of patients discontinuing the study is lower than for
oxydodone [3]. This should lead to lower costs, not to higher costs.6. Table 1 at http://dx.doi.org/10.1016/j.jval.2012.12.006 shows
the same opioid abuse rates for tapentadol and oxycodone—
data from the RADARS system [4] suggest otherwise.
In our view, these data inaccuracies lead to an unfavorable
cost-effectiveness result for tapentadol, which we feel should be
either more fully justiﬁed, or corrected.
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